• Clovis to Apply for Expanded FDA Approval for Rubraca in Ovarian Cancer Patients
  • CARMA Advances Funding for Development of Immunotherapy Program to Treat Metastatic Solid Tumors
  • Geisinger Health System Hits Milestone with 150,000 Participants in Biobank and DNA Sequencing Study
  • Update on FOCUS Trial of CA4P in Ovarian Cancer Expected in Late Summer
  • Siamab to Present Preclinical Data for ST1 Antibody Drug Conjugates at 2017 BIO International Convention
  • Better Delivery Method Sought for High-dose Chemo Known to Treat Residual Ovarian Cancer
  • Lynparza Prolongs Progression-Free Survival, Sustains Quality of Life in Women with BRCA-Mutated Relapsed Ovarian Cancer
  • Several Studies on Track for Ovarian and Breast Cancer Vaccine TPIV 200
  • Blood Sugar and GLUT1 Protein May Be Biomarkers for Ovarian Cancer, Study Finds
  • Zejula Continues to Show Promise in Recurrent Ovarian Cancer Patients
  • Oregovomab Combo Benefits Ovarian Cancers More Than Chemo Alone, Study Reports
  • Most Ovarian Cancer Patients Want Doctors to Discuss the Unknowns, Survey Indicates